Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: A phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5)
European Journal of Cancer, 06/25/09
Magnusson M et al. - In a trial to investigate if the same drugs could prevent radiation-induced side-effects in women with breast cancer, it was concluded that the combination of pentoxifylline and vitamin E was safe and may be used for prevention of some radiation-induced side-effects.
Methods- Women with breast cancer were treated for 12 mos with 400 mg pentoxifylline tid or placebo, in combination with 100 mg vitamin E tid, starting 1–3 mos after the completion of radiotherapy.
- Primary end-point was passive abduction of the shoulder, and the secondary endpoint was difference in arm volumes.
- 83 pts were included in the study; 42 in the pentoxifylline + vitamin E group and 41 in the placebo + vitamin E group.
- Both treatments were generally well tolerated.
- 7 pts were withdrawn from the treatment due to disease progression; 4 in the pentoxifylline group and 3 in the placebo group.
- At inclusion, pts had impaired passive abduction of the shoulder.
- During treatment, both the groups improved significantly.
- Median improvement from baseline was 3.7° on pentoxifylline and was 9.4° in the placebo group, but no difference between the groups was detected.
- Arm volumes increased over time in the placebo group (1.04%), but not on pentoxifylline (0.50%), and differed significantly between the groups.
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Pomegranate fruit extract impairs invasion and motility in human breast cancer
Integrative Cancer Therapies , 10/12/09
Today in Diagnostics/Radiology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
BMC Cancer, 10/21/09
Today in Side Effects...keeping you current
Receive free subspecialty "5-minute updates" via email
Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study
Annals of Oncology, 10/16/09
Effect of topical morphine (mouthwash) on oral pain due to chemotherapy- and/or radiotherapy-induced mucositis: a randomized double-blinded study
Journal of Palliative Medicine, 10/16/09
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer
Cochrane Reviews, 10/09/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


